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To the Editor: Studies of HIV prevalence in sub-Saharan Africa 
usually focus on the age group 15 - 49 years.1 However, estimates of 
HIV prevalence in older people are required for health policy and 
planning. The health care and social needs of older HIV-infected 
individuals differ from younger people; e.g. because of different 
co-morbidities,2 different responses to antiretroviral treatment 
(ART),3 and the central role of older adults in African households.4 
In South Africa, a nationally representative survey provided first 
insights into the burden of HIV in the population ≥50 years of age, 
reporting HIV prevalence in men/women as 10.4%/10.2% (in the 
age group 50 - 54 years), 6.2%/7.7% (55 - 59 years), and 3.5%/1.8% 
(≥60 years).5 However, the South African HIV epidemic is highly 
heterogeneous6 with substantial variation by geographic location and 
ethnic group, limiting the value of national averages.
Method
We measured HIV prevalence in the age group ≥50 years in one of the 
rural communities hardest hit by the HIV epidemic in South Africa7-9 
and compared it with national estimates. In addition, we estimated 
HIV incidence in this age group to assess whether HIV infections 
were acquired only among younger ages or also in older adults. We 
used data from the longitudinal population-based HIV surveillance 
conducted at the Wellcome Trust-funded Africa Centre for Health 
and Population Studies (Africa Centre), University of KwaZulu-Natal 
(UKZN), in Umkhhanyakude District, northern KwaZulu-Natal.10,11 
HIV status was assessed by ELISA antibody testing of dried blood spot 
samples in the Africa Centre virology laboratory.10 Ethics permission 
for the study was obtained from the Medical Ethics Committee at 
UKZN. Statistical analyses were performed using STATA 10.0.
The surveillance area is largely rural, but includes a township and 
peri-urban informal settlements. The resident population consists of 
about 65 000 Zulu-speaking people.11 From 2003 to 2006, the annual 
HIV surveillance was limited to the age groups 15 - 54 years (for 
men) and 15 - 49 years (for women). From 2007 onwards, all adults 
≥15 were eligible to participate. In 2007 (2008), 2 791 (2 684) people 
≥50 years of age participated in the HIV surveillance. The crude HIV 
prevalence among participants was 9.4% (95% confidence interval 
(CI) 8.4 - 10.6) in 2007, and 9.5% (95% CI 8.4 - 10.6) in 2008.
Results
Table I shows HIV prevalence estimates by sex and 5-year age group 
for 2007 and 2008. When we accounted for selective HIV survey 
non-response by sex and age, the HIV prevalence estimates differed 
only slightly from the crude estimates: 10.6% in 2007 (11.9% in men 
and 8.9% in women) and 8.9% in 2008 (12.9% in men and 7.8% 
in women). A previous study found that controlling for selection 
on observed factors did not significantly affect HIV prevalence 
estimates in sub-Saharan Africa;12 more recent studies demonstrate 
that selection on unobserved factors can substantially bias results in 
HIV surveys in the region.13,14 In the case that people know their HIV 
status and refuse to participate in an HIV survey if they are HIV-
positive, non-response is clearly correlated with unobserved HIV 
status. Future studies need to investigate the extent to which selection 
on unobserved factors could have biased the estimates shown here.
We regressed HIV status against demographic and geographic 
factors in multivariable logistic regression: sex, age (50 - 64 v. ≥65 
years old), marital status (currently married; widowed, separated or 
divorced; single), place of residence (urban or peri-urban v. rural), 
distance from the participant’s household to the nearest primary road 
(<5 km v. ≥5 km), and distance from the household to the nearest 
primary health care clinic (<3 km v. ≥3 km). For individuals who 
participated in the HIV surveillance in 2007 and 2008, we used data 
from the 2008 surveillance round.
Factors independently associated with positive HIV status were: 
age ≥65 years (adjusted odds ratio (aOR) 0.20, p<0.001); currently 
married (aOR 0.46, p=0.001); being widowed, separated or divorced 
(aOR 0.47, p=0.029); and distance from household to nearest primary 
road ≥5 km (aOR 0.57, p=0.028). Associations with sex, place of 
residence, and distance to the nearest primary healthcare clinic did 
not reach significance at the 5% level.
These findings are plausible. Firstly, past studies in this demographic 
surveillance area found steadily declining HIV prevalence with age in 
men and women after peak HIV prevalence in the middle age groups,15 
and the age relationship found in this regression extents this pattern 
to the oldest age groups. Secondly, the length of time that individuals 
spent without a married partner is likely to be associated with HIV 
risk factors, such as lifetime partners and number of risky sex acts, and 
hence with positive HIV status. In turn, at any given age, individuals 
who are currently married, widowed, separated or divorced will have 
spent less time without a married partner than individuals who have 
been single throughout their entire lifetime. Finally, investigations 
in the Africa Centre demographic surveillance area showed that 
HIV prevalence in individuals <50 years old decreases with distance 
from the primary roads, a relationship suggesting that easy access to 
transport increases the risk of HIV acquisition.16 We find that this 
pattern generalises to older populations.
Comparing 5-year age groups, HIV prevalence estimates in older 
people in this rural setting are considerably higher than national 
South African estimates (Table I).5 This is not surprising as the study 
took place in a community in South Africa with the most severe 
HIV epidemic among younger people.7-9 Moreover, local coverage 
with ART and HIV care has expanded rapidly since 2005. At the 
end of 2008, an estimated 21% of all HIV-infected individuals in the 
community were receiving ART.17 Such high ART coverage probably 
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significantly increased average survival of HIV-infected individuals,18 
which we would expect to lead to increasing HIV prevalence rates.
For HIV incidence estimation, we selected all individuals ≥50 
years old who participated at least twice in the HIV surveillance in 
the period 2006 - 2008, and tested HIV-negative in 2006 or 2007. 
Among the 1 549 participants (410 men, 1 139 women) included 
in the sample for HIV incidence analysis, 8 (4 women, 4 men) 
seroconverted in 1 575 person-years at risk. HIV incidence was 0.5 
(95% CI 0.3 - 1.0) per 100 person-years overall; 0.9 in men (95% CI 
0.3 - 2.4) and 0.4 in women (95% CI 0.1 – 1.0).
Estimates of HIV incidence in older people are rare, because 
longitudinal HIV surveys commonly limit data collection to younger 
adults. We show that HIV incidence among older adults is high in 
a community in rural KwaZulu-Natal. This finding is important 
but may not be surprising: global studies have consistently found 
substantial sexual activity in older men and women.19
HIV infection in older people has several distinct features – the 
speed of disease progression increases with age at infection,20 
older people do not respond as quickly to ART, and age-related 
conditions may limit HIV treatment options.21 HIV prevalence 
is likely to increase in future years as HIV-related mortality in 
younger HIV-infected people continues to decrease because of ART 
coverage.18 Although further studies are urgently needed to identify 
and understand the specific HIV treatment and prevention needs of 
older adults in rural South Africa, our findings suggest they should 
not be ignored.
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Should routine serological screening for HCV be mandatory in 
HIV/AIDS patients enrolling for HAART in South Africa?
Maemu P Gededzha, M Jeffrey Mphahlele, Azwidowi Lukhwareni, Selokela G Selabe
To the Editor: Globally, an estimated 170 million people (about 3% 
of the world’s population) have been infected with hepatitis C virus 
(HCV). HCV, a member of the Hepacivirus genus in the Flaviviridae 
family, possesses a single stranded, positive-sense RNA genome of 
approximately 9.6 kilobase (kb), and is the major cause of chronic 
hepatitis, cirrhosis and hepatocellular carcinoma.1 In Africa, HCV 
prevalence ranges from <3% in South Africa to >20% in Egypt. In 
South Africa, there is a low prevalence from 0.16% to 1.8%,2-5 but this 
is higher in high-risk individuals, e.g. 39.4% in haemophiliacs and 
4.8% in chronic dialysis patients.2
Some 4 - 5 million people globally are co-infected with HCV and 
human immunodeficiency virus (HIV).6 Co-infection with HCV 
and HIV is common owing to shared routes of transmission – via 
blood and blood products and sharing of needles for injecting drugs.7 
The introduction of highly active antiretroviral therapy (HAART) 
dramatically improved the management of HIV patients. However, 
co-infections with opportunistic infections such as HCV and hepatitis 
B virus (HBV) remain a major problem. Patients with HIV/HCV 
co-infection have less immune reconstitution than patients with 
HIV infection alone,8 and HAART may worsen the outcome of HCV 
disease, through enhancement of drug-induced hepatotoxicity.9
South Africa has scaled up HAART for treatment of HIV/AIDS 
in the public health sector since April 2003. However, research 
programmes to monitor the efficacy of HAART in HIV/AIDS 
patients co-infected with HBV and HCV do not exist. We have shown 
that 63% of HIV-positive South African patients initiating HAART 
have past or present HBV infection.10 However, few data exist on the 
burden of HCV prevalence in HIV patients. One study demonstrated 
a low prevalence of 1.9%,11 and another a high prevalence of 13.4% 
in KwaZulu-Natal.12
Methods
We investigated the burden of HCV co-infection in HIV-positive 
patients enrolling for HAART at a tertiary hospital in Pretoria. The 
study population comprised 653 serum samples stored at -70oC 
from adult HIV/AIDS patients who were candidates for HAART at 
Tshepang Clinic, Dr George Mukhari Hospital (DGMH), Pretoria, 
from 2004 to 2006. The Research, Ethics and Publication Committee 
of the University of Limpopo, Medunsa Campus, approved the study. 
All sera were screened for anti-HCV marker using the AxSYM assays 
version 3.0 (Abbott Laboratories, North Chicago) following the 
manufacturer’s instructions.
Owing to limited serum volumes to confirm the initial screening 
results with a second serological assay, all anti-HCV positives 
(samples with S/CO, i.e. ratio of the sample rate (S) to the cut-off 
rate (CO) for each sample and control) above 5.23 and preliminary 
positives (samples with S/CO between 1.00 and 5.00) were subjected 
to in-house qualitative reverse transcription-polymerase chain 
reaction (RT-PCR) assay. Viral RNA was extracted from serum with 
the QIAmp viral mini RNA kits (Qiagen Gmbh, Germany), followed 
by PCR targeting of the highly conserved 5’-untranslated region 
(UTR) as previously described with slight modifications.13 PCR 
positive samples were sequenced to confirm the specificity of the 
PCR products (SpectruMedix SCE 2410 Genetic Analysis System, 
LLC, PA).
Results
Only 1.2% (8/653) of samples were positive for anti-HCV, with S/CO 
values ranging from 5.69 to 37.8. Of these 8 samples, HCV RNA was 
detected in only one, which had the highest anti-HCV titre of 37.8 
(Table I). Sequencing confirmed that the RT-PCR product is HCV-Corresponding author: S Selabe (selokela@yahoo.com)
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